Home › NDC Lookup › RxCUI directory › RxCUI 993683

24 HR bupropion hydrobromide 522 MG Extended Release Oral Tablet [Aplenzin] — RxCUI 993683

RxNorm drug concept · Semantic branded drug
RxCUI 993683 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI993683
Official name24 HR bupropion hydrobromide 522 MG Extended Release Oral Tablet [Aplenzin]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as24 HR Aplenzin 522 MG Extended Release Oral Tablet; Aplenzin 522 MG 24HR Extended Release Oral Tablet
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)2,390 prescriptions · 19 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bupropion: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Bupropion treats major depressive disorder. Some extended-release products, like Aplenzin and bupropion XL, can also prevent seasonal affective disorder, the depression that return...
  • Take it by mouth exactly as prescribed. XL tablets are taken once in the morning, with or without food, and must be swallowed whole. Your doctor will usually raise the dose gradual...
  • The most common ones are dry mouth, nausea, trouble sleeping, dizziness, headache, anxiety and tremor. Call your doctor right away if you have a seizure, new suicidal thoughts, sev...
  • It's best to limit or avoid alcohol. Rare neuropsychiatric events and lower alcohol tolerance have been reported. Never suddenly stop heavy drinking while on bupropion without talk...
📖 Read our full Bupropion guide →

🕸️ Concept Web — How 24 HR bupropion hydrobromide 522 MG Extended Rel... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR bupropion hydrobromide 522 MG Extended Release Oral Tablet [Aplenzin] RxCUI 993683

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Bupropion 42347
    • Bupropion hydrobromide 993548
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aplenzin 835486
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bupropion Extended Release Oral Tablet 378354
    • Bupropion hydrobromide Extended Release Oral Tablet 2645852
    • Bupropion Oral Product 1151365
    • Bupropion Pill 1151366
    • Bupropion hydrobromide Oral Product 2662509
    • Bupropion hydrobromide Pill 2663677
    • Bupropion Extended Release Oral Tablet [Aplenzin] 835488
    • Bupropion hydrobromide Extended Release Oral Tablet [Aplenzin] 2655096
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 24 HR bupropion hydrobromide 522 MG Extended Release Oral Tablet SCD · 993681
  • Bupropion hydrobromide 522 MG SCDC · 993680
  • Bupropion Extended Release Oral Tablet SCDF · 378354
  • Bupropion hydrobromide Extended Release Oral Tablet SCDFP · 2645852
  • Bupropion Oral Product SCDG · 1151365
  • Bupropion Pill SCDG · 1151366
  • Bupropion hydrobromide Oral Product SCDGP · 2662509
  • Bupropion hydrobromide Pill SCDGP · 2663677

Brand-Name Concepts

  • Bupropion hydrobromide 522 MG [Aplenzin] SBDC · 993682
  • Bupropion Extended Release Oral Tablet [Aplenzin] SBDF · 835488
  • Bupropion hydrobromide Extended Release Oral Tablet [Aplenzin] SBDFP · 2655096
  • Aplenzin Oral Product SBDG · 1168564
  • Aplenzin Pill SBDG · 1168565
  • Aplenzin BN · 835486

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 993683 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00187-5810-07 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5810-07) Aplenzin Bausch Health US, LLC 2008-04-23
00187-5810-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5810-30) Aplenzin Bausch Health US, LLC 2008-04-23
00187-5811-07 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5811-07) Aplenzin Bausch Health US, LLC 2008-04-23
00187-5811-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5811-30) Aplenzin Bausch Health US, LLC 2008-04-23
00187-5812-07 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5812-07) Aplenzin Bausch Health US, LLC 2008-04-23
00187-5812-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5812-30) Aplenzin Bausch Health US, LLC 2008-04-23
Observed labelers: Bausch Health US, LLC (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.